
Artera Raise $90M for AI-Enabled Cancer Therapy
Artera, a CA-based startup that offers an AI-enabled test aimed at personalizing therapy for prostate cancer patients, has raised $90 million from technology and healthcare investors Johnson & Johnson, TIME Ventures, Koch Disruptive Technologies, Coatue, Walden Catalyst Ventures, The Factory, Breyer Capital and angel investors.
The company intends to use the funds to invest in the development of tests to support therapy personalization in other cancers.
Artera’s multimodal AI-powered test for prostate cancer patients, called ArteraAI Prostate Test, helps predict the potential benefits of therapy and a patient’s prognosis by analyzing the patient’s clinical data and biopsy images.
“The American Cancer Society estimates that more than 288,000 new cases of prostate cancer will arise in 2023, with more than 34,000 deaths. AI has given clinicians and patients a powerful weapon in the fight against this disease,” said Andre Esteva, co-founder and CEO of Artera.
Founded in 2015, Artera has now raised $135 million. The company was formerly known as Well Health and rebranded itself in October.
